by | Apr 27, 2022 | Chang, Ju Fang, Singh, Nathan
— Technology Description
Researchers in Nathan Singh’s lab at Washington University have developed a construct for cell therapy that combines facets of existing CAR-T therapy and the endogenous T cell receptor (TCR) to better regulate adoptive cell activation. Unlike the traditional TCR, this …
by | Jan 13, 2022 | DeSelm, Carl
— Technology Description
Researchers at Washington University in St. Louis have developed a genetic method to produce chimeric antigen receptor dendritic cells (CAR-DCs) for the treatment of solid tumors. The team generated a CAR that drives differentiation of cDC1s and mediates tumor-specific uptak…
by | Sep 17, 2021 | Crowley, Jan, Henderson, Jeffrey P., Robinson, John
— Technology Description
Researchers in Prof. Jeffrey Henderson’s laboratory have developed a method of analyzing metabolic biomarkers from fecal samples to more accurately identify C. difficile infection (CDI) and distinguish between symptomatic and asymptomatic colonization. CDI is currently …
by | Sep 9, 2021 | Choi, Kyunghee, Kabir, Ashraf Ul, Krchma, Karen
— Technology Description
Researchers in Kyunghee Choi’s lab at Washington University in St. Louis have identified a novel target, Myct1, that modulates tumor angiogenesis and anti-tumor immune response. Myct1 inhibition with siRNA blocks angiogenesis and promotes infiltration of cytotoxic T ly…
by | Sep 2, 2021 | Schreiber, Robert
— D42m1 is a methycholanthrene (MCA) induced sarcoma cell line generated in 129S6 strain RAG2 gene targeted mice. These cells are highly immunogenic and are rejected when transplanted into syngeneic naive wild type mice.
F244 is an MCA induced sarcoma cell line generated in wild type 129S6 mice. Thes…